03/05/2018 The Association A ContraCORrent contributes to start a new research project in congenital cardiopathies 03/05/2018 In the last weeks it has been possible to start the inclusion of patients in this project. The ContraCORrent Association has once again collaborated with the https://www.vallhebron.com/es/especialidades/cardiopatias-congenitas-del-adolescente-y-el-adulto" Integrated Unit of Congenital Cardiopathies of Adolescents and Adults of Vall d'Hebron - Sant Pau. With the continuous contributions made by the Association, it has been possible to finance part of a new research project in the field of patients with this type of disease. In particular, their help has made it possible to launch the project "Characterisation of long-term cardiac reinnervation in patients with transposition of the great vessels repaired with an arterial switch," which has been able to initiate the inclusion of patients in recent weeks.Dr. Laura Dos Subirà, principal investigator of the study and member of the research group on http://es.vhir.org/portal1/grup-equip.asp?s=recerca&contentid=186805 Cardiovascular Diseases of VHIR highlights that "the interest and involvement of the patients themselves in spreading and promoting research into their disease is very important and stimulating for the researchers themselves." The Association organizes annual festive events to raise funds for research into congenital heart disease. In the 2017 edition, 2,145 euros were collected, which have been allocated entirely to the implementation of this project. Dr. Laura Dos Subirà insists that "congenital cardiopathies in adults are a new pathology in which the search is very fundamental." ContraCORrent was born from people with congenital heart disease, family and friends who saw that "research is a fundamental pillar to be able to face the challenges that will come and the moments that unfortunately we have to live. Unfortunately, the resources allocated to research are scarce and therefore our objective is to organize charitable events to raise funds to invest them fully and directly in VHIR for research into congenital heart disease," explains Benjamin Vilageliu, president of the Association and affected by a congenital heart disease. Twitter LinkedIn Facebook Whatsapp